No Data
A Piece Of The Puzzle Missing From Shijiazhuang Yiling Pharmaceutical Co., Ltd.'s (SZSE:002603) Share Price
Insiders the Biggest Winners as Shijiazhuang Yiling Pharmaceutical Co., Ltd.'s (SZSE:002603) Market Cap Rises to CN¥26b
Shijiazhuang Yiling Pharmaceutical: 2024 Interim Performance Forecast
Shijiazhuang Yiling Pharmaceutical (002603.SZ): Received the Drug Registration Application Acceptance Notice for Benamorphene Injection.
On July 10th, Gelonhui reported that Yiling Pharmaceuticals (002603.SZ) has received the "Acceptance Notice" issued by the National Medical Products Administration, and the new drug registration application for "benzamide propyphenazone injection" submitted by the company has been formally accepted. Benzamide propyphenazone injection is a new chemical drug independently developed by the company. Benzamide propyphenazone injection belongs to the class of arylalkanoic acid analgesic and anti-inflammatory drugs in its chemical structure, which can inhibit the synthesis of prostaglandins and exert analgesic and anti-inflammatory effects by blocking inflammatory mediators. Its clinical indications include: postoperative mild to moderate pain in adults, and combined with opioid analgesics for the treatment of moderate to severe pain after surgery.
Express News | Shijiazhuang Yiling Pharmaceutical Says It Sees H1 Net Profit Down 60-73% Y/Y
The Five-year Decline in Earnings for Shijiazhuang Yiling Pharmaceutical SZSE:002603) Isn't Encouraging, but Shareholders Are Still up 116% Over That Period
Benign Growth For Shijiazhuang Yiling Pharmaceutical Co., Ltd. (SZSE:002603) Underpins Its Share PriceNo Data
